carvedilol sandoz carvedilol 25 mg tablets blister pack
sandoz pty ltd - carvedilol, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate - hypertension. data have not been provided to support the use of this drug in renovascular disease. symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators).
carvedilol sandoz carvedilol 12.5 mg tablets blister pack
sandoz pty ltd - carvedilol, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate; iron oxide yellow; iron oxide red - hypertension. data have not been provided to support the use of this drug in renovascular disease. symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators).
carvedilol sandoz carvedilol 6.25 mg tablets blister pack
sandoz pty ltd - carvedilol, quantity: 6.25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate; iron oxide yellow - hypertension. data have not been provided to support the use of this drug in renovascular disease. symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators).
tamsulosin sandoz sr tamsulosin hydrochloride 400 microgram prolonged release tablet
sandoz pty ltd - tamsulosin hydrochloride, quantity: 400 microgram - tablet, modified release - excipient ingredients: quinoline yellow; purified talc; polyethylene oxide; cochineal; microcrystalline cellulose; magnesium stearate; hyprolose; butylated hydroxytoluene; macrogol 400; titanium dioxide; iron oxide black; hypromellose; colloidal anhydrous silica - for the relief of lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph).
paroxetine sandoz paroxetine (as hydrochloride) 20mg tablet blister pack
sandoz pty ltd - paroxetine hydrochloride, quantity: 22.2 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; mannitol; titanium dioxide; sodium starch glycollate; colloidal anhydrous silica; hypromellose; copovidone; purified talc - paroxetine sandoz is indicated for the treatment of : - major depression and for the prevention of relapse of depressive symptoms - obsessive compulsive disorder (ocd) and prevention of relapse of ocd - panic disorder and for the prevention of relapse of panic disorder - social anxiety disorder/social phobia - general anxiety disorder - post-traumatic stress disorder.
sildenafil sandoz pharma sildenafil (as citrate) 50 mg tablet blister pack
sandoz pty ltd - sildenafil citrate, quantity: 70.2 mg (equivalent: sildenafil, qty 50 mg) - tablet, uncoated - excipient ingredients: indigo carmine aluminium lake; croscarmellose sodium; microcrystalline cellulose; calcium hydrogen phosphate; magnesium stearate; copovidone; saccharin sodium - sildenafil sandoz pharma is indicated for the treatment of erectile dysfunction in adult males. sildenafil sandoz pharma is not indicated for use by women.
azacitidine sandoz azacitidine 100 mg powder for injection vial
sandoz pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine is indicated for the treatment of patients with: ? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ? chronic myelomonocytic leukemia [cmmol (10%-29% marrow blasts without myeloproliferative disorder)], ? acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated.
pomalidomide sandoz pomalidomide 4 mg capsule blister pack
sandoz pty ltd - pomalidomide, quantity: 4 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; maltodextrin; sodium stearylfumarate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; indigo blue; erythrosine; shellac - pomalidomide sandoz, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. pomalidomide sandoz, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior threatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
pomalidomide sandoz pomalidomide 3 mg capsule blister pack
sandoz pty ltd - pomalidomide, quantity: 3 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; maltodextrin; sodium stearylfumarate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; indigo blue; shellac - pomalidomide sandoz, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. pomalidomide sandoz, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior threatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
aripiprazole sandoz
sandoz new zealand limited - aripiprazole 10mg - tablet - 10 mg - active: aripiprazole 10mg excipient: hyprolose iron oxide red lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.